ContraFect_LOGO_Web.jpg
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
November 13, 2020 08:33 ET | ContraFect Corporation
CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the...
ContraFect_LOGO_Web.jpg
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
October 26, 2020 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 07:30 ET | ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
ContraFect_LOGO_Web.jpg
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
June 17, 2020 07:30 ET | ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect_LOGO_Web.jpg
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
June 15, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
May 26, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
May 21, 2020 22:59 ET | ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 21, 2020 16:09 ET | ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
May 15, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
May 11, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...